Shilpa Medicare Limited, Unit 4, Jadcherla, Telangana, India had Europe GMP inspection by AGES, Austria from 22 January, 2024 until 26 January, 2024. This inspection has concluded with two minor observations.

The previous EU - GMP inspection for this facility was in January 2020.

This Unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets.

The company intends to respond to the two minor observations within the stipulated time and is committed for the satisfactory resolution of the inspectional observations and sustained cGMP compliance.